Original Source(s)
Related Content
Complex Hematologic Malignancy Management in a TP53-Mutated Patient: Balancing Disease Control and Quality of Life
Cytogenetic and molecular testing revealed a complex karyotype and a TP53 mutation, placing her disease in an adverse-risk category.
Clinical Trials May Misrepresent True Thromboembolic Risks From Cancer Drugs
Researchers have identified that the reporting of venous and arterial thrombotic events in cancer clinical trials is inconsistent and potentially inaccurate, according to a comments article published ...
by Lisa Astor
April 24, 2026
-
9 min
Epcoritamab Plus R<sup>2</sup> in Follicular Lymphoma: A Potential New Treatment Standard
In patients with follicular lymphoma who received at least one prior line of therapy, the combination of the bispecific antibody epcoritamab-bysp and rituximab–lenalidomide (R2) reduced the risk of di...
April 22, 2026
-
9 min
